JP7624995B2 - アトラセンタンによるｉｇａ腎症を治療する方法 - Google Patents

アトラセンタンによるｉｇａ腎症を治療する方法 Download PDF

Info

Publication number
JP7624995B2
JP7624995B2 JP2022537007A JP2022537007A JP7624995B2 JP 7624995 B2 JP7624995 B2 JP 7624995B2 JP 2022537007 A JP2022537007 A JP 2022537007A JP 2022537007 A JP2022537007 A JP 2022537007A JP 7624995 B2 JP7624995 B2 JP 7624995B2
Authority
JP
Japan
Prior art keywords
weeks
subject
atrasentan
iga nephropathy
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022537007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507739A (ja
JPWO2021126977A5 (enExample
Inventor
フィリップ トーマス フローリヒ，
アンドリュー ジェイムズ キング，
チダンバラム ラマチャンドラン，
サラ ベス ヌーンバーグ，
Original Assignee
チヌーク セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チヌーク セラピューティクス，インコーポレイテッド filed Critical チヌーク セラピューティクス，インコーポレイテッド
Publication of JP2023507739A publication Critical patent/JP2023507739A/ja
Publication of JPWO2021126977A5 publication Critical patent/JPWO2021126977A5/ja
Priority to JP2024218275A priority Critical patent/JP2025060686A/ja
Application granted granted Critical
Publication of JP7624995B2 publication Critical patent/JP7624995B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2022537007A 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法 Active JP7624995B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024218275A JP2025060686A (ja) 2019-12-17 2024-12-12 アトラセンタンによるｉｇａ腎症を治療する方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962949115P 2019-12-17 2019-12-17
US62/949,115 2019-12-17
US202063005003P 2020-04-03 2020-04-03
US63/005,003 2020-04-03
US202063072699P 2020-08-31 2020-08-31
US63/072,699 2020-08-31
US202063084739P 2020-09-29 2020-09-29
US63/084,739 2020-09-29
US202063125205P 2020-12-14 2020-12-14
US63/125,205 2020-12-14
PCT/US2020/065311 WO2021126977A1 (en) 2019-12-17 2020-12-16 Methods of treating iga nephropathy with atrasentan

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024218275A Division JP2025060686A (ja) 2019-12-17 2024-12-12 アトラセンタンによるｉｇａ腎症を治療する方法

Publications (3)

Publication Number Publication Date
JP2023507739A JP2023507739A (ja) 2023-02-27
JPWO2021126977A5 JPWO2021126977A5 (enExample) 2023-12-26
JP7624995B2 true JP7624995B2 (ja) 2025-01-31

Family

ID=76478538

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537007A Active JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法
JP2024218275A Pending JP2025060686A (ja) 2019-12-17 2024-12-12 アトラセンタンによるｉｇａ腎症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024218275A Pending JP2025060686A (ja) 2019-12-17 2024-12-12 アトラセンタンによるｉｇａ腎症を治療する方法

Country Status (13)

Country Link
US (11) US20210353593A1 (enExample)
EP (1) EP4076652B1 (enExample)
JP (2) JP7624995B2 (enExample)
KR (1) KR20230015874A (enExample)
CN (3) CN116327758A (enExample)
AU (1) AU2020404984A1 (enExample)
BR (1) BR112022012075A2 (enExample)
CA (1) CA3161516A1 (enExample)
IL (1) IL293921A (enExample)
MX (1) MX2022007471A (enExample)
PH (1) PH12022551456A1 (enExample)
TW (1) TWI875895B (enExample)
WO (1) WO2021126977A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293921A (en) 2019-12-17 2022-08-01 Chinook Therapeutics Inc Methods for treating iga kidney disease with atresantan
CN114910647A (zh) * 2022-05-07 2022-08-16 浙江大学 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用
WO2023220930A1 (en) * 2022-05-17 2023-11-23 Increvet, Inc. Veterinary pharmaceutical formulations cross-references to related applications
CA3252232A1 (en) * 2022-05-19 2023-11-23 Chinook Therapeutics, Inc. METHODS OF TREATMENT OF SEGMENTAL AND FOCAL GLOMERULOSCLEROSIS WITH ATRASENTAN
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
IL320469A (en) * 2022-10-28 2025-06-01 Chinook Therapeutics Inc Treatment of IGA nephropathy with an endothelin receptor antagonist and an APRIL-binding antibody
AU2023378052A1 (en) 2022-11-07 2025-05-29 Chinook Therapeutics, Inc. Combination of endothelin receptor antagonist and glucocorticoid for treating iga nephropathy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110319333A1 (en) 2010-06-24 2011-12-29 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
JP2016530311A (ja) 2013-09-12 2016-09-29 アッヴィ・インコーポレイテッド 腎臓疾患治療のためのアトラセンタン・マンデル酸塩
JP2016530238A (ja) 2013-07-08 2016-09-29 アッヴィ・インコーポレイテッド アトラセンタンを含有する安定化医薬剤型
JP2019530713A (ja) 2016-10-13 2019-10-24 レトロフィン， インコーポレイテッド 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5236940A (en) 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US20020062121A1 (en) 1995-05-16 2002-05-23 Karl Tryggvason Perfusion apparatus and methods for pharmaceutical delivery
PT885215E (pt) 1996-02-13 2006-08-31 Abbott Lab Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
US20040191774A1 (en) 2001-09-11 2004-09-30 Moskowitz David W Endothelin-1 promoter polymorphism
MXPA04009234A (es) 2002-03-22 2005-01-25 Kissei Pharmaceutical Agente preventivo o terapeutico para enfermedades renales.
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US20030229906A1 (en) 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
JP2008513481A (ja) 2004-09-17 2008-05-01 アボット・ラボラトリーズ アトラセンタン塩酸塩の結晶形２
WO2006034085A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form of atrasentan hydrochloride
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
WO2006034094A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride
WO2007109244A2 (en) 2006-03-21 2007-09-27 Morehouse School Of Medicine Novel nanoparticles for delivery of active agents
MX2008012276A (es) * 2006-03-27 2008-10-08 Genentech Inc Metodos para el tratamiento de alteraciones del riñon.
SG174050A1 (en) 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
CA2667364A1 (en) 2007-01-16 2008-07-24 Musc Foundation For Research Development Compositions and methods for diagnosing, treating, and preventing prostate conditions
CN101801936B (zh) 2007-07-31 2012-10-03 吉利德科罗拉多公司 安立生坦的代谢物和衍生物
CA2904447C (en) 2007-08-22 2017-01-03 Abbvie Deutschland Gmbh & Co Kg Therapy for complications of diabetes
US20120083421A1 (en) 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
EP2413930A4 (en) 2009-03-31 2012-09-26 Ligand Pharm Inc ORAL FORMULATION OF ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS BASED ON DIPHENYLSULFONAMIDE TO TREAT HIGH BLOOD PRESSURE AND DIABETIC NEPHROPATHY
WO2011070049A1 (en) 2009-12-09 2011-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
WO2012014663A1 (ja) 2010-07-28 2012-02-02 日本電気硝子株式会社 蛍光体封入用毛細管の製造方法、蛍光体封入用毛細管、波長変換部材及び波長変換部材の製造方法
HK1220209A1 (zh) * 2013-03-08 2017-04-28 Abbvie Inc. 治疗急性肾损伤的方法
AU2014259961A1 (en) 2013-04-30 2015-11-05 Abbvie, Inc. Methods for improving lipid profiles using atrasentan
WO2016073846A1 (en) * 2014-11-07 2016-05-12 Abbvie Inc. Methods of treating ckd using predictors of fluid retention
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US20170014386A1 (en) 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
MA43260A (fr) * 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
UA127339C2 (uk) 2016-01-05 2023-07-26 Юніверсіті Оф Лестер СПОСІБ ПРОФІЛАКТИКИ АБО ЗМЕНШЕННЯ УРАЖЕННЯ НИРОК У СУБ'ЄКТА, ЩО СТРАЖДАЄ НА СТЕРОЇДЗАЛЕЖНУ ІМУНОГЛОБУЛІН-А-НЕФРОПАТІЮ (IgAN)
CN110177549A (zh) 2016-11-23 2019-08-27 坎莫森特里克斯公司 治疗局灶性节段性肾小球硬化的方法
SG11202002975YA (en) 2017-10-11 2020-04-29 Chemocentryx Inc Treatment of focal segmental glomerulosclerosis with ccr2 antagonists
MA51203A (fr) 2017-11-30 2020-10-07 Idorsia Pharmaceuticals Ltd Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline
US20220304979A1 (en) 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
IL293921A (en) * 2019-12-17 2022-08-01 Chinook Therapeutics Inc Methods for treating iga kidney disease with atresantan
JP2023521169A (ja) 2020-04-10 2023-05-23 チヌーク セラピューティクス，インコーポレイテッド 糖尿病性腎疾患の処置方法
US20220243994A1 (en) 2021-02-04 2022-08-04 Northrop Grumman Systems Corporation Metal woodpile capillary wick

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110319333A1 (en) 2010-06-24 2011-12-29 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
JP2016530238A (ja) 2013-07-08 2016-09-29 アッヴィ・インコーポレイテッド アトラセンタンを含有する安定化医薬剤型
JP2016530311A (ja) 2013-09-12 2016-09-29 アッヴィ・インコーポレイテッド 腎臓疾患治療のためのアトラセンタン・マンデル酸塩
JP2019530713A (ja) 2016-10-13 2019-10-24 レトロフィン， インコーポレイテッド 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物

Also Published As

Publication number Publication date
KR20230015874A (ko) 2023-01-31
CN116173014A (zh) 2023-05-30
JP2023507739A (ja) 2023-02-27
WO2021126977A1 (en) 2021-06-24
US20210353593A1 (en) 2021-11-18
US20230129646A1 (en) 2023-04-27
US11998526B2 (en) 2024-06-04
CN113272013A (zh) 2021-08-17
WO2021126977A9 (en) 2021-07-22
US20220288027A1 (en) 2022-09-15
US20240108599A1 (en) 2024-04-04
JP2025060686A (ja) 2025-04-10
US12370174B2 (en) 2025-07-29
IL293921A (en) 2022-08-01
US20220288026A1 (en) 2022-09-15
TW202130350A (zh) 2021-08-16
EP4076652A1 (en) 2022-10-26
US20230355580A1 (en) 2023-11-09
US20220304978A1 (en) 2022-09-29
EP4076652A4 (en) 2024-01-03
CA3161516A1 (en) 2021-06-24
MX2022007471A (es) 2022-08-17
US20230364055A1 (en) 2023-11-16
US20250281454A1 (en) 2025-09-11
AU2020404984A1 (en) 2022-07-14
BR112022012075A2 (pt) 2022-08-30
US11491137B2 (en) 2022-11-08
US20250120945A1 (en) 2025-04-17
EP4076652B1 (en) 2025-12-03
US20230355579A1 (en) 2023-11-09
PH12022551456A1 (en) 2023-10-23
TWI875895B (zh) 2025-03-11
US12121509B2 (en) 2024-10-22
CN116327758A (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
JP7624995B2 (ja) アトラセンタンによるｉｇａ腎症を治療する方法
EP4188389B1 (en) Dapagliflozin for use in methods of treating chronic kidney disease
US20220304979A1 (en) Methods of reducing disease flares
WO2022148403A1 (zh) 靶向il-17c的抑制剂在治疗炎症相关慢性肾脏疾病中的用途
US20250352511A1 (en) Methods of treating focal segmental glomerulosclerosis with atrasentan
BR122023026537A2 (pt) Uso de atrasentan para tratar nefropatia por iga
HK40059453A (en) Methods of treating iga nephropathy with atrasentan
US20230226041A1 (en) Compounds for the treatment of viral infections
NZ716669A (en) Multiple myeloma treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231218

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240322

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240322

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240527

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241212

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250121

R150 Certificate of patent or registration of utility model

Ref document number: 7624995

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150